Novatis

Novatis company information, Employees & Contact Information

Explore related pages

Related company profiles:

Fondée en 2009, NOVATIS est une agence web tunisienne, spécialisée en solutions interactives, création site Internet, e-commerce, multimédia, Nous mettons à votre disposition nos équipes d’experts pour désigner, réaliser, développer, héberger, maintenir et promouvoir vos sites Internet. Nous déployons pour vous les meilleures solutions interactives pour maximiser l’impact visuel et votre image.

Company Details

Employees
90
Founded
-
Address
Centre Urbain Nord, Boulevard De La Terre, Résidence Malek Center, Bloc B / 7ème Étage - Appartement B7-1,tunisia
Phone
+33 01 84 23 13 48
Email
he****@****aris.fr
Industry
Advertising Services
NAICS
Marketing Consulting Services
Website
novatis.tn
HQ
Tunis, tunis
Looking for a particular Novatis employee's phone or email?

Novatis Questions

News

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) - Novartis

Novartis to acquire Tourmaline Bio, complementing cardiovascular pipeline with pacibekitug for the treatment of atherosclerotic cardiovascular disease (ASCVD) Novartis

Novartis plans to invest $23 billion in US sites as Trump renews drug tariff threats - Reuters

Novartis plans to invest $23 billion in US sites as Trump renews drug tariff threats Reuters

Novartis To Invest $23B In U.S. Facilities - Business Facilities

Novartis To Invest $23B In U.S. Facilities Business Facilities

John Novatis Obituary and Online Memorial (2011) - Legacy obituary

John Novatis Obituary and Online Memorial (2011) Legacy obituary

Our commitment to ethical and responsible use of Artificial Intelligence (AI) - Novartis

Our commitment to ethical and responsible use of Artificial Intelligence (AI) Novartis

Research and development - Novartis

Research and development Novartis

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA - Novartis

New Novartis Phase III data demonstrate meaningful efficacy and safety results of intrathecal onasemnogene abeparvovec in broad patient population with SMA Novartis

Oncology research at Novartis - Novartis

Oncology research at Novartis Novartis

Immunology disease research at Novartis - Novartis

Immunology disease research at Novartis Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) - Novartis

Novartis receives FDA accelerated approval for Fabhalta® (iptacopan), the first and only complement inhibitor for the reduction of proteinuria in primary IgA nephropathy (IgAN) Novartis

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 - Novartis

Novartis continues strong momentum of sales growth with margin expansion, reaches key innovation milestones in 2024 Novartis

People and culture - Novartis

People and culture Novartis

Therapeutic areas - Novartis

Therapeutic areas Novartis

Managed access programs - Novartis

Managed access programs Novartis

Climate - Novartis

Climate Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer - Novartis

FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer Novartis

Early careers - Novartis

Early careers Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA - Novartis

Novartis presents new data on safety and efficacy of Zolgensma, including maintained and improved motor milestones in older and heavier children with SMA Novartis

US Biomedical Research internship programs - Novartis

US Biomedical Research internship programs Novartis

From black holes to AI driven drug discovery – collaboration wins the day - Novartis

From black holes to AI driven drug discovery – collaboration wins the day Novartis

Sub-Saharan Africa - Novartis

Sub-Saharan Africa Novartis

The 2025 Eurovision Song Contest - Novartis

The 2025 Eurovision Song Contest Novartis

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab - Novartis

Novartis strengthens immunotherapy pipeline with option, collaboration and license agreement with BeiGene for TIGIT inhibitor ociperlimab Novartis

About - Novartis

About Novartis

The data42 program shows Novartis’ intent to go big on data and digital - Novartis

The data42 program shows Novartis’ intent to go big on data and digital Novartis

Novartis terminates phase 2 osteoarthritis trial testing ADAMTS-5 inhibitor - Fierce Biotech

Novartis terminates phase 2 osteoarthritis trial testing ADAMTS-5 inhibitor Fierce Biotech

Novartis pays PeptiDream $180M as radiopharma big bang continues - Fierce Biotech

Novartis pays PeptiDream $180M as radiopharma big bang continues Fierce Biotech

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran) - Novartis

World-first agreement between Novartis and the NHS enables broad and rapid access to first-in-class cholesterol-lowering medicine Leqvio® ▼(inclisiran) Novartis

Achieving 100% renewable electricity - Novartis

Achieving 100% renewable electricity Novartis

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond - Novartis

Novartis reinforces commitment to patient access, pricing a EUR 1.85 billion sustainability-linked bond Novartis

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment - BioSpace

Novartis Doubles Down on Argo Pact With Fresh $5.2B Commitment BioSpace

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader - Novartis

Novartis enters agreement to acquire AveXis Inc. for USD 8.7 bn to transform care in SMA and expand position as a gene therapy and Neuroscience leader Novartis

New drug manufacturing tools change pharma chemistry - Novartis

New drug manufacturing tools change pharma chemistry Novartis

Bringing virtual reality to the lab - Novartis

Bringing virtual reality to the lab Novartis

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia - Novartis

Novartis expands Kymriah® manufacturing footprint with first-ever approved site for commercial CAR-T cell therapy manufacturing in Asia Novartis

Novatis Group - Nonwovens Industry

Novatis Group Nonwovens Industry

Taking on obesity - Novartis

Taking on obesity Novartis

Stepping toward regenerative medicine for diabetes - Novartis

Stepping toward regenerative medicine for diabetes Novartis

Novatis treatment improves vision - Hospital Pharmacy Europe

Novatis treatment improves vision Hospital Pharmacy Europe

'Surprised and disappointed' with Novatis decision - Pacific Edge CE - RNZ

'Surprised and disappointed' with Novatis decision - Pacific Edge CE RNZ

Top Novatis Employees

Free Chrome Extension

Find emails, phones & company data instantly

Find verified emails from LinkedIn profiles
Get direct phone numbers & mobile contacts
Access company data & employee information
Works directly on LinkedIn - no copy/paste needed
Get Chrome Extension - Free

Aero Online

Your AI prospecting assistant